Abstract
Importance of the field: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 30% of all lymphomas. I-131 tositumomab is a radiommunoconjugate of 131I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL. Areas covered in this review: This review describes the clinical pharmacology of I-131 tositumomab, dosing and administration guidelines, and the key clinical trials providing evidence of its efficacy and safety in patients with FL, transformed, or other aggressive B-NHL, in combination with chemotherapy, or its incorporation in transplant conditioning regimens. This review also covers safety and regulatory concerns regarding the use of I-131 tositumomab. What the reader will gain: This review critically appraises the clinical trials behind approval of I-131 tositumomab as a second-line agent for FL and also outlines the data supporting its use in the upfront setting. Take home message: I-131 tositumomab is a safe and effective option for patients with recurrent, refractory, or transformed FL and carries promise in the upfront treatment of FL, aggressive B-NHL, and as a transplant conditioning regimen.
Original language | English (US) |
---|---|
Pages (from-to) | 1271-1278 |
Number of pages | 8 |
Journal | Expert Opinion on Biological Therapy |
Volume | 10 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2010 |
Keywords
- Follicular lymphoma
- I-131 tositumomab
- Lymphoma
- Monoclonal antibody
- Radioimmunoconjugates
- Radioimmunotherapy
- Transplant
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry